Molecular Devices Forms Scientific Advisory Board
News Dec 27, 2012
Molecular Devices, LLC, has announced the formation of its Scientific Advisory Board (SAB).
Comprising experts from a range of fields including stem cell research, biotherapeutics and cell signalling, the SAB will advise on strategy, product applications and product innovation, with the aim of identifying evolving customer needs and ensuring that the Molecular Devices products continue to deliver maximum value.
The SAB has been formed to provide scientific input into new product development, and to keep Molecular Devices focused on customer needs for products that support leading edge research.
These products include systems such as plate readers, imaging systems, or automated electrophysiology platforms, as well as emerging technologies.
Members of the Molecular Devices SAB are:
• Prof Sean J. Morrison, Director of the Children's Research Institute and Mary McDermott Cook Chair in Pediatric Genetics at University of Texas Southwestern, and Investigator of the Howard Hughes Medical Institute.
Prof Morrison is an expert in stem cell biology and the mechanisms by which stem cells are hijacked by cancer cells to enable neoplastic proliferation and metastasis.
• Prof Tobias Meyer, Chair of the Department of Chemical & Systems Biology at Stanford University School of Medicine. Prof Meyer’s areas of expertise are the fields of pharmacology and signal transduction.
His laboratory is developing microscopy and mathematical modeling approaches to understand how cells make decisions and regulate complex processes such as cell proliferation and cell migration.
• Prof Paul Johnston, Associate Professor of the Department of Pharmaceutical Sciences at University of Pittsburgh. Prof Johnston pioneered the use of high content imaging in drug discovery, and is an innovator of cell based approaches for lead generation and optimization. He developed numerous high throughput screening assays and hit assessment campaigns for kinases, transporters, GPCRs and ion channel targets.
• Prof Tobin J. Dickerson, Assistant Professor in the Department of Chemistry at Scripps Research Institute and founding member of the Worm Institute of Research and Medicine (WIRM). Prof Dickerson brings expertise in neural stem cell differentiation, protein-ligand interaction screening, HTS assay development and medicinal chemistry for diagnosis and treatment of chronic infections including the discovery of potent small molecule inhibitors of botulinum neurotoxin.
• Dr Pam Hawley-Nelson, Associate Director for Process Cell Culture at MedImmune. Dr Hawley-Nelson brings 18 years of experience in research and development of novel protein expression technologies, and in the development of cell lines for production of antibody pharmaceuticals.
"We are very pleased to bring together these key thought leaders to establish our Scientific Advisory Board," commented Kevin Chance, President of Molecular Devices.
Chance continued, "Their deep insight into the emerging needs of researchers in the life sciences will be instrumental in directing innovation at Molecular Devices. Securing the interest of and direct interaction with these world class scientists through our SAB reflects the commitment the company has made to being a scientific leader in the market."
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE